Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$5.13
+3.4%
$4.49
$3.42
$7.64
$288.38M1.941.58 million shs1.73 million shs
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$2.38
$2.76
$2.12
$5.80
$236.38M2.021.51 million shs2.58 million shs
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
$2.10
+4.0%
$1.94
$0.77
$4.08
$290.39M1.4913,989 shs1.10 million shs
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
$4.93
+1.2%
$4.60
$3.13
$26.84
$74.06M2.74291,830 shs215,340 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-1.59%+4.53%+17.26%-21.39%-30.34%
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
+7.21%-13.61%-7.39%-28.31%-26.09%
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
+1.00%+13.17%+18.82%-40.24%+31.17%
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
+0.41%+10.68%+15.13%-19.90%-77.45%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.4221 of 5 stars
0.02.00.00.02.40.80.6
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
1.3412 of 5 stars
3.52.00.00.01.80.00.0
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
3.6996 of 5 stars
4.63.00.00.01.65.00.0
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
2.179 of 5 stars
3.52.00.00.02.21.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
3.00
Buy$10.67348.18% Upside
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
3.11
Buy$13.13525.00% Upside
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
3.00
Buy$62.221,162.11% Upside

Current Analyst Ratings Breakdown

Latest JSPR, ACB, AQST, and CMPX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/15/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$80.00 ➝ $65.00
5/13/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$38.00 ➝ $33.00
5/9/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $10.00
4/28/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
4/22/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/21/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$24.00 ➝ $24.00
4/21/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
4/4/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$10.00 ➝ $24.00
4/2/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
4/2/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
(Data available from 5/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$320.81M0.90$0.19 per share26.35$8.18 per share0.63
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$57.56M4.11N/AN/A($1.59) per share-1.50
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
$850K341.64N/AN/A$1.17 per share1.79
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
N/AN/AN/AN/A$7.03 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-$48.62M$0.05102.6211.66N/A0.42%0.59%0.42%6/19/2025 (Estimated)
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$7.87M-$0.52N/AN/AN/A-59.75%N/A-33.96%N/A
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
-$42.49M-$0.41N/AN/AN/AN/A-32.37%-30.67%N/A
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
-$64.46M-$5.24N/AN/AN/AN/A-67.64%-58.53%N/A

Latest JSPR, ACB, AQST, and CMPX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$0.17-$0.24-$0.07-$0.24$12.23 million$8.72 million
5/12/2025Q1 2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
-$1.17-$1.41-$0.24-$1.41N/AN/A
5/8/2025Q1 2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
-$0.12-$0.12N/A-$0.12N/AN/A
3/5/2025Q4 2024
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$0.14-$0.19-$0.05-$0.19$13.11 million$11.87 million
2/27/2025Q4 2024
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
-$0.10-$0.11-$0.01-$0.11N/AN/A
2/27/2025Q4 2024
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
-$1.27-$1.62-$0.35-$1.62N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
N/AN/AN/AN/AN/A
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
N/AN/AN/AN/AN/A
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.07
3.30
1.60
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
N/A
6.37
5.91
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
N/A
31.84
31.84
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
N/A
7.61
7.61

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
32.45%
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
68.43%
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
79.85%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
8.35%
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
29.80%
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
2.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,34056.21 million54.85 millionOptionable
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
16099.32 million84.02 millionOptionable
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
20138.28 million98.38 millionNot Optionable
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
2015.02 million14.60 millionOptionable

Recent News About These Companies

Jasper Therapeutics files $300M mixed securities shelf

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$5.13 +0.17 (+3.43%)
Closing price 04:00 PM Eastern
Extended Trading
$5.07 -0.06 (-1.17%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Aquestive Therapeutics stock logo

Aquestive Therapeutics NASDAQ:AQST

$2.38 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$2.38 +0.00 (+0.21%)
As of 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Compass Therapeutics stock logo

Compass Therapeutics NASDAQ:CMPX

$2.10 +0.08 (+3.96%)
Closing price 04:00 PM Eastern
Extended Trading
$2.08 -0.02 (-0.71%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Jasper Therapeutics stock logo

Jasper Therapeutics NASDAQ:JSPR

$4.93 +0.06 (+1.23%)
Closing price 04:00 PM Eastern
Extended Trading
$4.93 0.00 (0.00%)
As of 06:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.